As a monotherapy, PVCT has ONCS beat. The problem is that is as far as it goes for them. 25% (person, not lesion) CR is good, but they need a combination trial to be of any significance, along with serious monetary issues. Right now, I have no worries about PVCT beating ONCS, and have seen no evidence of any other competitor that has a chance of outdoing ONCS.
News 
Market Data 
Discover 
